Your oncology patient needs atezolizumab. The payer's PA comes back: patient must first try and fail a different checkpoint inhibitor that's on their preferred formulary. The ordering physician says that isn't clinically appropriate. This is a step therapy override situation.
Disclaimer: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk.
What Step Therapy Actually Is
Step therapy — sometimes called "fail first" — is a payer cost management tool that requires patients to try one or more preferred (usually less expensive) treatments before the payer will authorize the requested drug or therapy. It's common in specialty oncology, biologics, and specialty genetics (pre-implantation genetic testing in some managed Medicaid plans).
The logic is straightforward from the payer's perspective: why pay for a $15,000/month drug if the patient might respond to a $3,000/month drug first? The clinical problem is that step therapy protocols are designed around populations, not individual patients. An individual patient may have a biomarker profile, comorbidity, or prior treatment history that makes the preferred-step drug clinically inappropriate or contraindicated.
Step therapy requirements don't eliminate access — they create a procedural barrier that you can override with the right documentation and the right legal framing.
When You Can File an Override
Override eligibility depends on the plan type and the state you're operating in. Know this before you spend time building an override request.
Fully insured commercial plans in states with step therapy laws: A growing number of states have enacted step therapy override statutes. Texas SB 1742 (effective 2021) is among the most specific — it requires commercial plans to grant an override when certain clinical criteria are met, with defined timelines for payer response. Louisiana and other states have similar statutes. If your patient's plan is fully insured (not self-insured) and the state has a law, you have statutory override rights with teeth.
Self-insured ERISA plans: Here's the hard part. Self-insured employer plans are governed by ERISA (29 USC §1133) and largely preempt state step therapy laws. Your override argument in an ERISA plan relies on the plan's own internal documents — the Summary Plan Description and the coverage criteria — rather than state law. ERISA appeals are slower and harder to win, but you still have the internal and external appeal pathway.
Medicare Advantage: MA plans are subject to CMS oversight and cannot have step therapy protocols that conflict with CMS's clinical standards. For oncology drugs in particular, CMS has guidance that MA plans should not require step therapy in clinical situations where the requested drug has a distinct indication or biomarker indication that the step drug does not. Know this and use it.
Medicare Part D: Part D plans must have a formulary exception process. Under 42 CFR §423.578, a prescriber can request a formulary exception when the requested drug is medically necessary and the formulary alternative is contraindicated or clinically inappropriate for the patient.
The Clinical Grounds for Override
Most step therapy override statutes and plan documents recognize these override criteria:
Contraindication: The required step drug is clinically contraindicated for this patient. Document the specific contraindication — not "patient can't tolerate it" but the specific comorbidity, drug-drug interaction, or allergy that makes the step drug inappropriate.
Clinical failure: The patient already tried and failed the required step drug in the current or a previous clinical episode. Past history counts. Document the prior use, the dates, and the clinical outcome (progression, toxicity, inadequate response).
Disease progression risk: Requiring the patient to try the step drug first would cause irreversible harm or worsen outcomes. This applies in oncology when time matters — requiring a patient with rapidly progressive disease to spend weeks trialing an inappropriate therapy is a patient safety argument, not just a clinical preference.
Biomarker-directed therapy: The requested drug is indicated based on a specific biomarker that the step drug doesn't address. If the patient's tumor has a specific mutation that the requested drug targets and the step drug doesn't, the drugs aren't clinically equivalent. NCCN guidelines support this argument for biomarker-driven therapy selection.
Building the Override Request
The override request is a clinical letter, not an administrative complaint. The ordering physician signs it; your team prepares the supporting package.
The letter should: state which override criterion applies and why, cite the specific clinical facts that establish it, reference the applicable payer policy language or state statute, and ask for a response within the payer's required timeframe (Texas SB 1742, for example, requires response within 3 business days for urgent situations and 10 business days for standard requests).
Attach: the treating physician's full clinical notes documenting the patient's history, any prior treatment documentation (dates, drugs, outcomes), pathology and biomarker results if the argument is biomarker-directed, and the relevant NCCN guideline section showing the requested drug's indication.
If you're in Texas or another state with a step therapy law, cite the statute by number in the letter. Payers respond differently to a letter that says "pursuant to Texas SB 1742, we are requesting a step therapy protocol exception" than one that just argues clinical appropriateness. The statutory citation signals you know your rights.
If the Override Is Denied
Step therapy override denials follow the same appeal pathway as any other medical necessity denial. Internal appeal, then external review for fully insured plans.
Under ACA §2719 and applicable state laws, you have the right to external review by an independent organization for non-grandfathered fully insured plans. External reviewers are independent of the payer and decide based on clinical standards and coverage documents. For oncology step therapy, where NCCN guidelines and biomarker evidence are well-documented, external review can be highly effective.
For ERISA plans, external review depends on the plan document. Some ERISA plans voluntarily participate in external review; others don't. The plan's SPD governs.
Document everything: dates, contacts, reference numbers, clinical arguments made at each step. If you eventually escalate to a state insurance department complaint (for fully insured plans), that record is your evidence.
Sources
- Texas SB 1742 (step therapy override requirements — commercial fully insured plans)
- 42 CFR §423.578 (Part D formulary exceptions process)
- 29 USC §1133 (ERISA full and fair review)
- ACA §2719 (independent external review — non-grandfathered fully insured plans)
- 45 CFR §147.136 (internal claims and appeals — ACA-compliant plans)
- NCCN Clinical Practice Guidelines (NCCN.org) — biomarker-directed therapy indications